Enstilar® Foam in the Treatment of Chronic Plaque Psoriasis in Patients With Skin of Color

Inclusion Criteria:

Provide written, signed and dated informed consent prior to initiating any study-related activities.
Male or female >18 years of age at the time of screening
Fitzpatrick Skin phototype IV-VI, non-white race/ethnicity, including but not limited to - --African Americans, Asians, Pacific Islanders and Hispanics.
Clinical diagnosis of chronic plaque-type psoriasis of the body
Plaque psoriasis with ≥2% Body Surface Area (BSA) involvement (may include scalp involvement), PASI Score ≥ 2, IGA mod 2011 score of 2 or greater (based on scale of 0-4)
Females of childbearing potential (FCBP) must have a negative pregnancy test at Screening and Baseline. While using investigational product and for at least 28 days after last application of investigational product, FCBP who engage in activity in which conception is possible must use one of the approved contraceptive options d
Must be in general good health as judged by the Investigator, based on medical history and physical examination.

Exclusion Criteria:

Form of diagnosed psoriasis other than chronic plaque psoriasis (i.e. guttate, erythrodermic, pustular)
Diagnosis of other active, ongoing skin diseases or skin infections that may interfere with examination of psoriasis lesions
Ongoing use of other psoriasis treatment including but not limited to topical or systemic corticosteroids, other topical medications (i.e. coal tar), oral or biologic medications for the treatment of psoriasis, and UV therapy. The following washout periods will be required: 2 weeks for topical therapy; 2 weeks for phototherapy; 12 weeks for biologic or targeted therapies; 4 weeks for other systemic therapies
Use of oral estrogen therapy, excluding oral contraceptive pills
Women who are pregnant, nursing, or of child-bearing potential who are unwilling to use appropriate method(s) of contraception.
Patients unwilling to limit exposure to UV light
Current significant medical problems that, in the discretion of the investigator, would put the patient at significant risk
Patients with disorders of calcium metabolism and/or hypercalcemia
Use of any investigational drug within 4 weeks prior to randomization, or 5 pharmacokinetic/pharmacodynamics half-lives, if known (whichever is longer)
History of allergy to any component of the IP